Download The Team - DNAdigest

Nucleobase is seeking seed funding of £250k to prototype the API and market it with partner institutions.
Nucleobase will make efficient ethical genomic data sharing possible:
Sharing and access to DNA sequencing data is limited due to privacy
concerns and interoperability difficulties. The lack of sharing stops the
progress of genomics research, affecting all disease research from
cancers to rare diseases.
The
Team
Fiona Nielsen
@glyn_dk
Founder & CEO
of DNA Digest.
#bioinformatics #genetics
#computational #genomics
Victor Szilagyi,
@semiot
Director of
Nucleobase.
#UI #UX #design #product
#strategy #development
Jelena Aleksic,
@firegenome
Advisor of
Nucleobase.
#genomics #bioinformatics
#contract #strategy #writing
Let’s have a
Conversation.
@dnadigest
[email protected]
[email protected]
07852239062
10a Capper Street, Wayra
London, WC1E 6JA
The DNAdigest platform is an API to securely query anonymised data:
Nucleobase will develop and market the DNAdigest platform as a data
broker solution providing on-demand access to aggregated statistics
accessed securely across data locations. The result of each query is
returned the user in a secure manner which keeps raw data fully
anonymised through aggregation.
Direct benefit for an exponentially growing market:
Our target users are clinical geneticists and genetic researchers, both
public and private. The DNA sequencing market is growing at an
exponential rate (estimated 500k human genomes sequenced in
2015) and only a fraction of this data is currently made available for
the research market in personalised medicine. Through direct user
feedback, we have learnt our product has the potential to save
6months of the ~8 year $1.3bill drug discovery pipeline in pharma.
Worldwide impact:
DNAdigest will impact research in human health worldwide by
shortening the time for drug development and accelerate genetic
diagnosis from years to days. In addition, unlocking the silos of data
will open up whole new markets for products based on big data
DNAdigest Intellectual Property:
The underlying mechanism for data aggregation and anonymisation is
patented (Taysom & Cleevely) and has been applied before in the
context of marketing data. DNAdigest has a perpetual licence to apply
and sublicence this patented mechanism.
Subscription model for access and incentives for growing users:
Our business model is based on charging subscription fee tiered by
the amount of queries available per month. The fees will be heavily
discounted for institutions that connect their data for access through
the platform API, and such providing a financial incentive for
institutions to make their data available for secure queries.
Profitable, sustainable and reaching market in 12months:
The DNAdigest platform will launch our MVP for our first paying
customers within 12 months of our first funding round. We are
seeking 250k in investment please do get in touch to learn more
about us and have a look at our investor deck.